News & Articles

Licensing with a global enzyme provider for two Optimer reagents in research and diagnostics

New data show Optimer delivery vehicle could be used in precision medicines across diverse fibrotic diseases

New test format enhances commercialisation potential

Successful project delivery of Optimer binders with proven function as vaccine adjuvants

New collaboration will evaluate Aptamer’s fibrotic liver delivery vehicles with siRNA

Optimer binders will be developed for use in a cervical cancer blood test

The goal is the development of a lateral flow test for early disease detection

Novel Optimer binders from Aptamer Group promise a highly effective antibody-alternative for diagnostics, with excellent target recognition, consistent supply and temperature stability for simple global logistics

Partnership includes initial upfront payments and will potentially deliver recurring revenues for over 10 years

This partnership aims to offer an accelerated route to market rapid test technologies

The new collaborative project aims to explore the potential use of aptamers as treatment for myeloid malignancies